HC Wainwright Forecasts Weaker Earnings for Sight Sciences

Sight Sciences, Inc. (NASDAQ:SGHT) – Research analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Sight Sciences in a report issued on Thursday, November 5th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.45) for the year, down from their previous forecast of ($0.40). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Sight Sciences’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Sight Sciences’ Q4 2026 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.02) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.20) EPS.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). The business had revenue of $24.92 million during the quarter, compared to analysts’ expectations of $23.55 million. Sight Sciences had a negative return on equity of 43.91% and a negative net margin of 32.13%.

SGHT has been the topic of a number of other reports. Citigroup boosted their price target on shares of Sight Sciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a research note on Monday, October 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sight Sciences in a research note on Wednesday, November 4th. Piper Sandler restated an “overweight” rating and issued a $12.00 price objective (up from $9.00) on shares of Sight Sciences in a report on Thursday, November 5th. Wall Street Zen raised shares of Sight Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, UBS Group upped their target price on shares of Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Sight Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $9.62.

Sight Sciences Stock Performance

Shares of Sight Sciences stock opened at $10.75 on Monday. The stock has a market capitalization of $597.49 million, a price-to-earnings ratio of -20.67 and a beta of 2.44. The company has a debt-to-equity ratio of 0.71, a current ratio of 5.04 and a quick ratio of 4.72. The business has a 50-day moving average of $8.81 and a 200 day moving average of $6.13. Sight Sciences has a 12 month low of $3.38 and a 12 month high of $11.16.

Hedge Funds Weigh In On Sight Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of Sight Sciences during the second quarter worth about $16,710,000. GSA Capital Partners LLP purchased a new stake in shares of Sight Sciences during the second quarter worth approximately $908,000. Bank of New York Mellon Corp acquired a new stake in Sight Sciences in the second quarter valued at approximately $495,000. Bank of America Corp DE acquired a new stake in Sight Sciences in the second quarter valued at approximately $520,000. Finally, SCS Capital Management LLC acquired a new stake in Sight Sciences in the second quarter valued at approximately $488,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Insider Buying and Selling

In related news, CFO James Rodberg sold 7,208 shares of the business’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $8.85, for a total transaction of $63,790.80. Following the completion of the transaction, the chief financial officer directly owned 216,829 shares of the company’s stock, valued at $1,918,936.65. The trade was a 3.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Brenton Taylor sold 2,988 shares of the company’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $8.85, for a total value of $26,443.80. Following the sale, the executive vice president owned 261,990 shares in the company, valued at approximately $2,318,611.50. This trade represents a 1.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 47,646 shares of company stock valued at $429,157. 30.40% of the stock is currently owned by company insiders.

Sight Sciences Company Profile

Sight Sciences, Inc. is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease. Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.